Search

Omaveloxolone

[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Forasartan

Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. … Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension.

Megestrol acetate

17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been u...

1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.

Haemophilus influenzae b polysaccharide-tetanus conjugate

Brompheniramine

Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

Ensartinib

[A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … [A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously

Otenabant

Otenabant has been investigated for the treatment of Obesity.

Trofinetide

, making trofinetide the first and only treatment approved for Rett syndrome in the European Union. … [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive